Nexstim: Our Comment On the Rights Issue
Research Note
2021-04-08
08:59
Redeye adjusts its fair value range following Nexstim’s completed rights issue. The company has secured funding for its ongoing operations and further pilot studies on an accelerated treatment for its depression therapy (NBT System).
FT
Fredrik Thor
Disclosures and disclaimers